Introduction {#Sec1}
============

For 70 years brain abnormalities in autism spectrum disorder (ASD) were viewed as static \[[@CR1]\], and age-associated alterations were beyond the scope of neuropathological studies. However, more recent clinical and morphological studies have disclosed evidence of developmental and age-associated changes and have suggested a dynamic nature of structural and functional changes throughout the lifespan of individuals with autism. The dichotomous concept of autism distinguishes between the "early-onset" pattern of clinical deficits, which emerge in the first year of life, and regressive autism, which is diagnosed in children who develop typically for the first year but lose acquired skills and develop autistic symptoms in the second year of life \[[@CR2]\]. Development of the autistic phenotype typically takes three years and consists of several steps, suggesting a progressive involvement of brain structures and neuronal networks. The earliest signs noted by approximately 50% of parents are nonspecific and include behavioral changes ranging from marked irritability to alarming passivity, poor eye contact, and lack of response to parental voice or interaction \[[@CR3]\]. Behavioral modifications at the age of 12 months cross several functional domains including visual attention, imitation, social responses, motor control, and reactivity \[[@CR4]\]. Mild, atypical language deficits detected at the age of 12 months typically become severe delays by 24 months \[[@CR3],[@CR5]\]. At three years of age, all diagnostic features, including difficulties in social reciprocity and communication, and restricted/repetitive interests, are usually present \[[@CR6]\]. The improvement in daily living skills during adolescence and in the early 20s and the plateau in skills during the late 20s \[[@CR7]\] indicate that the clinical phenotype is formed during early childhood but undergoes further modifications during adolescence and adulthood.

Early childhood brain overgrowth is widely cited as evidence of age-associated developmental structural alterations linked to clinical regression in autism. At birth, the head circumference of neonates later diagnosed with autism is in the range of normal, but by 1 or 2 years of age, a rapid increase is typically observed \[[@CR8]-[@CR10]\], which is followed by growth inhibition resulting in only a 2% larger brain size in autistic adults \[[@CR11]\] or a smaller brain size in comparison to control subjects \[[@CR12]\]. The regression with the loss of previously acquired skills, including verbal, nonverbal, and social abilities, reported in 15% to 62% of individuals with autism \[[@CR13]-[@CR17]\] suggests that clinical deterioration might be associated with structural changes. The period of acceleration of head growth overlaps with the onset of behavioral changes, whereas deceleration coincides with behavioral worsening in the second year of life \[[@CR18]\]; however, the cellular nature of accelerated brain growth is unknown.

Among people with autism, one of the relatively common components of brain pathology is the presence of developmental abnormalities \[[@CR19],[@CR20]\] contributing to epilepsy. However, the probability of development of epilepsy is a function of age \[[@CR21]\], with a bimodal distribution of the onset of seizures, one peak occurring before the age of 5 years, and the other after the age of 10 \[[@CR22]\]. The highest prevalence is observed in patients older than 12 years \[[@CR23]\]. The frequency of epilepsy in autism has been reported to range from 5% to 38.3% \[[@CR21]\], but long-duration video-electroencephalogram (EEG) telemetry of children with ASD and the history of regression reveal an epileptiform EEG in another 46% of ASD cases \[[@CR24]\]. The bimodal distribution of the onset of seizures appears to be another marker of the age-associated alterations that might be triggered by biochemical and structural alterations \[[@CR25]\].

The high prevalence of intellectual deficit and epilepsy in ASD indicates that all three disorders share elements of their pathophysiology \[[@CR26]\], but that each of these disorders has its own timing of onset and dynamic of clinical expression. Neuropathological studies cannot monitor structural changes during the first three years when the autistic phenotype is emerging but before children have been diagnosed. However, the significantly smaller volume of neuronal soma in 14 of 16 examined brain regions in 4- to 8-year-old children with autism suggests that neuronal size alterations are present earlier than 4 years of age and contribute to the clinical phenotype \[[@CR27]\]. The fact that only three regions show a neuronal volume deficit in 11- to 23-year-old autistic individuals indicates biochemical and structural remodeling of the brain in teenagers and young adults.

One may assume that these alterations of neuronal soma volume result from changes in the neuronal nucleus or cytoplasm, or both. Nuclear size is only partially regulated by chromatin organization \[[@CR28]\], and experimental studies indicate that alterations of cytoplasm components have a significant impact on nuclear size and function \[[@CR29]\]. The overall goal of this study was to establish the course of volume changes of the neuronal nucleus and soma cytoplasm throughout the lifespan, assuming that an altered trajectory reflects neuronal development and maturation defects. The broad spectrum of clinical features of autism (impaired communication and social skills, repetitive and stereotypic behaviors, intellectual deficits \[[@CR30]\], epilepsy or epileptogenic activity in the majority of autistic individuals \[[@CR25],[@CR26]\], and other clinical alterations) suggests multiregional rather than topographically limited brain pathology. The aim of our study of neuronal nucleus and cytoplasm volumes in 16 brain regions in autistic and control subjects was to characterize the global pattern of subcellular changes that may correspond to a broad spectrum of behavioral alterations in autism, including intellectual deficits and epilepsy. To detect differences between the course of autism-specific and control-specific nucleus and cytoplasm alterations throughout the lifespan 4- to 8-, 11- to 23-, and 29- to 60-year-old autistic and control subjects were examined.

Materials and methods {#Sec2}
=====================

The brain hemispheres used in this project were preserved for several parallel studies designed to detect the global pattern of developmental abnormalities of neurogenesis, migration, and dysplastic changes \[[@CR19],[@CR31]\] and to establish the global pattern of alterations of the number and size of neurons in the cerebral cortex \[[@CR27],[@CR32]-[@CR35]\], subcortical structures, cerebellum, and brainstem \[[@CR27],[@CR35]\]. Provisionally, 39 brains were assigned to the stereological study, including 21 brains from autistic individuals and 18 from controls. However 11 brain samples (seven autistic and four controls) were excluded because postmortem examination revealed pathology not related to autism, changes associated with mechanisms of death, or postmortem autolysis, which may distort the results of stereological estimates. Application of these criteria resulted in inclusion of brains of 14 individuals diagnosed with autism, including 10 males and four females 4 to 60 years of age, and 14 control subjects, including nine males and five females 4 to 64 years of age.

Diagnosis of autism was confirmed with the Autism Diagnostic Interview-Revised (ADI-R) \[[@CR6]\]. The intellectual disability of eight subjects (61%) ranging from mild to severe was determined with the Wechsler Intelligence Scale for Children III and the Woodcock-Johnson Tests of Achievement-Revised. Seven of the 14 autistic subjects (50%) were diagnosed with seizures, and in five cases, death was seizure-related (36%). Neuropathological examination revealed focal developmental abnormalities of neurogenesis, migration, and dysplastic changes in the brains of 92% of autistic subjects \[[@CR19]\].

The difference between the postmortem interval (PMI) in the control group (6--28 hours; 16.7 hours on average; standard deviation, SD ± 6.6 hours) and in the autistic group (8--50 hours; 21.9 hours on average; ± 11.4 hours) was insignificant. Also, the difference between the average weight of the brains in the autistic group (1,453 g) and in the control group (1,372 g) was insignificant. The brain hemisphere was fixed with 10% buffered formalin for an average of 408 days in the control group (range 52--1,819 days) and 905 days (range 75--4,560 days) in the autistic cohort. Neither the average time of brain hemisphere dehydration in ethyl alcohol (36 days in the control group and 38 days in the autistic group) nor the reduction of brain hemisphere weight during dehydration (47% ± 7% in the autistic and 45% ± 7% in the control group) were significantly different. Brain hemispheres were embedded in 8% celloidin \[[@CR36]\] and cut into serial 200-μm-thick sections that were stained with cresyl violet and mounted with Acrytol.

Stereological analysis {#Sec3}
----------------------

To establish the global pattern of neuronal volume alterations, the volume of the neuronal nucleus and cytoplasm was estimated in 16 brain structures/neuronal populations, including the amygdala, entorhinal cortex, Ammon's horn, claustrum, caudate nucleus, putamen, globus pallidus, nucleus accumbens, thalamus including the magno- and parvocellular layers of the lateral geniculate nucleus (LGN), substantia nigra, and magnocellular basal complex (MBC); Purkinje cells and dentate nucleus in the cerebellum; and the inferior olive in the brainstem. Neurons were distinguished from glial cells by using several morphological features including neuron size, shape, and spatial orientation typical for specific layers, sectors, and brain nuclei. Additional feature were the pattern of staining and distribution of nuclear chromatin, the distinct nucleolus in the majority of examined neuronal populations, and cytoplasm morphology. Small and round nuclei with uniform, intense staining of nuclear chromatin distinguished oligodendrocytes from astrocytes, which had large round nuclei with a small amount of dispersed chromatin and an undetectable nucleolus.

The volume of neuronal soma and nucleus was determined with the nucleator method \[[@CR37]\] using MicroBrightfield software (Stereo Investigator, version 7.003, MBF Bioscience, Williston, VT, USA). Five rays were used to estimate the volume of the cell and the nucleus. Five points of intersection of systematic randomly rotated radii with the nuclear and cell border were marked. The neuronal soma and cell nucleus volumes were estimated from the lengths of radial cellular segments. The volume of the cytoplasm was calculated as the difference between neuronal body and nucleus volume. Measurements were performed using a workstation consisting of an Axiophot II (Carl Zeiss, Goettingen, Germany) light microscope with Plan Apo objectives 1.25× (numerical aperture, N.A., 0.15) or 2.5× (N.A. 0.075) (border lines of region of interest), 40× (N.A. 0.75) or 63× (N.A. 0.9) (neuronal and nuclear measurements); a specimen stage with a three-axis, computer-controlled stepping motor system (Ludl Electronics; Hawthorne, NY, USA); and a CCD color video camera (CX9000 MBF Bioscience).

We used from four equidistant serial sections \[[@CR38]\] in structures with relatively uniform cytoarchitecture (caudate nucleus, putamen, and globus pallidus) to 12 or 14 serial sections in more heterogeneous structures such as the amygdala or Ammon's horn. An optical fractionator systematic random sampling scheme was applied using Stereo Investigator (MBF Bioscience). The number of virtual counting spaces was adjusted to region-specific numerical density and ranged from 59, in small neuronal groups in the MBC, to 664 for Purkinje cells with significant variations in the numerical density per counting space. To achieve a Schaeffer coefficient of error (CE) of less than 5%, the number of examined neurons per region in individual cases ranged from 153 in the MBC to 509 in the Ammon's horn. The volume of the nucleus and cytoplasm in the cytoarchitectural subdivisions of the amygdala, entorhinal cortex, Ammon's horn, and substantia nigra are presented as a mean value for the entire structure. Details of the applied methods and anatomical boundaries of the examined brain structures and their cytoarchitectural subdivisions have been described in detail in Wegiel et al. \[[@CR27]\].

Statistical analysis {#Sec4}
--------------------

This study analyzed the effect that autism has on nucleus and cytoplasm volume, with age-matched controls as a comparison group. Data have been post-stratified to adjust for the differing numbers of neurons sampled per individual so as to weight each individual equally. Any data points more than 1.5 times the interquartile range below the 25^th^ percentile or an equal amount above the 75^th^ percentile for each structure or subdivision were considered outliers and were omitted from analyses. The removed data accounted for 0.3% of all records.

Analyses were carried out separately for three groups of autistic cases: 4--8 years, 11--23 years, and 36--60 years of age. Three groups of controls were selected to provide age-matching at the group level. The age ranges for control groups were 4--8 years, 14--23 years, and 29--64 years of age. Our previous study of neuronal soma volume alterations throughout the lifespan revealed a significant neuron soma volume deficit in 14 of 16 examined regions in children with autism 4 to 8 years of age, but the number of regions with a significant deficit of neuronal soma volume decreased to three in autistic teenagers/young adults (11 to 23 years of age) and stabilized at four in subjects 36 to 60 years of age. To maintain compatibility of results from the previous study and this analysis of neuron nucleus and cytoplasm volume, the same age divisions were applied.

Comparisons were carried out across 16 regions. Adjustment for multiple comparisons was performed using the Benjamini-Hochberg method \[[@CR39]\] to maintain a false discovery rate (FDR) of 0.05. Accordingly, p values of 0.019 or less were considered statistically significant. Analyses were conducted using versions 11.1 and 12.1 of the Stata statistical package \[[@CR40],[@CR41]\].

Following the procedure developed in our previous analyses of the effects of potential confounders \[[@CR27]\] including PMI (in hours), fixation time (in days), brain weight (in grams), brain weight loss during processing and dehydration (as a percentage), duration of dehydration (in days), history of seizures, and sudden and unexplained death in patients with known epilepsy (SUDEP), analyses were controlled for the log of the PMI, days of dehydration, and weight loss during dehydration.

The statistical significance of the differences in mean neuronal volumes between autistic and control brains and between pairs of age ranges was computed in general linear mixed models adjusted for the autocorrelation of measurements within each brain by using the xtmixed procedure in version 12 of the Stata statistical package \[[@CR41]\]. This method takes into account the variance among measurements of each individual while assessing the significance of the differences between the brains of autistic and control individuals.

Results {#Sec5}
=======

Brain region--specific proportions between neuronal soma, nucleus, and cytoplasm volumes {#Sec6}
----------------------------------------------------------------------------------------

In 16 examined brain regions in 4- to 8-year-old control subjects, the mean volume of nuclei varied from 246 μm^3^ in small neurons in the putamen to 815 μm^3^ in the largest neurons in the substantia nigra (Table [1](#Tab1){ref-type="table"}). The percentage of cell volume occupied by the nucleus was the smallest in large neurons, such as Purkinje cells (5%), and the largest in small neurons such as in the nucleus accumbens (24%) (Figure [1](#Fig1){ref-type="fig"}).Table 1**The difference between the mean volume of neuronal nucleus in three age groups of control and autistic subjectsBrain structure4- to 8-year-old subjects11- to 23-year-old subjects29- to 64-year-old subjectsControlAutismControlAutismControlAutismMean ± SD (100%)Mean ± SD** ***p***  **\< (%)Mean ± SD (100%)Mean ± SD** ***p***  **\< (%)Mean (SD) (100%)Mean ± SD** ***p***  **\< (%)**Nucleus accumbens281 ± 44163 ± 49 -42% 0.001226 ± 52213 ± 54 0.959 ns239 ± 34253 ± 7 0.224 nsPurkinje cells575 ± 63394 ± 77 -31% 0.001561 ± 83552 ± 168 0.635 ns569 ± 63654 ± 189 0.368 nsClaustrum395 ± 32233 ± 371 -41% 0.001360 ± 49255 ± 67 -29% 0.001267 ± 16307 ± 76 0.841 nsThalamus645 ± 56371 ± 56 -42% 0.001439 ± 95433 ± 77 0.186 ns462 ± 68581 ± 103 0.035 nsGlobus pallidus625 ± 93503 ± 55 -19% 0.001417 ± 103479 ± 95 0.611 ns478 ± 60489 ± 75 0.918 nsDentate nucleus510 ± 168305 ± 152 0.104 ns448 ± 20489 ± 122 0.312 ns397 ± 53501 ± 128 + 26% 0.008Entorhinal cortex561 ± 67408 ± 49 -27% 0.001502 ± 110444 ± 98 -11% 0.002452 ± 69484 ± 102 0.465 nsAmygdala606 ± 24431 ± 74 -29% 0.001595 ± 60520 ± 88 0.691 ns548 ± 48498 ± 116 0.184 nsMagnocellular basal complex656 ± 45476 ± 45 -27% 0.001575 ± 46581 ± 51 0.051 ns558 ± 116611 ± 131 0.028 nsPutamen246 ± 39180 ± 32 -27% 0.014244 ± 52231 ± 51 0.443 ns213 ± 27223 ± 34 + 5% 0.004Caudate nucleus256 ± 54181 ± 52 0.269 ns229 ± 44234 ± 49 0.284 ns182 ± 26234 ± 56 + 28% 0.001Inferior olive613 ± 122507 ± 125 -17% 0.001525 ± 67553 ± 103 0.905 ns508 ± 68551 ± 73 0.481 nsMagnocellular LGN455 ± 66382 ± 85 0.364 ns457 ± 33483 ± 85 + 5% 0.001502 ± 20567 ± 36 + 13% 0.002Parvocellular LGN268 ± 50217 ± 47 -19% 0.005264 ± 25263 ± 48 0.145 ns284 ± 28335 ± 37 + 18% 0.001Substantia nigra815 ± 122756 ± 50 -7% 0.001811 ± 114816 ± 97 0.202 ns646 ± 56685 ± 65 0.057 nsAmmon's horn702 ± 40576 ± 72 -18% 0.001702 ± 72631 ± 79 0.246 ns683 ± 110706 ± 138 + 3% 0.002Significance levels computed controlling for post-mortem interval, days of fixation, days of dehydration, and weight loss during dehydration. Mean nucleus volume ± SD; SD, standard deviation; ns, not significant; LGN, lateral geniculate nucleus.Figure 1**Region-specific proportion between nucleus and neuron soma volume and the range of neuronal nucleus and cytoplasm volume deficit in children diagnosed with autism.** Percent of cell volume occupied by nucleus in 4- to 8-year-old control subjects illustrates neuron type-- or region-specific proportions between cell and nucleus volume, with the smallest contribution of nucleus to neuron volume in the largest neurons (Purkinje cell, 5%), and the largest contribution in the smallest neurons (nucleus accumbens, 24%). Neuronal nucleus volume deficits (control 100%) in 4- to 8-year old autistic subjects range from mild (\<10%) in the substantia nigra to profound (\>40%) in the n. accumbens, thalamus, and claustrum. The cytoplasm volume deficit is less prominent and ranges from 4% in the substantia nigra to 32% in the nucleus accumbens. PC, Purkinje cell; SN, substantia nigra; MBC, magnocellular basal complex; DN, dentate nucleus; GP, globus pallidus; LGNm, magnocellular layer of the lateral geniculate nucleus; IO, inferior olive; Th, thalamus; AH, Ammon's horn; Am, amygdala; LGNp, parvocellular layer of the lateral geniculate nucleus; EC, entorhinal cortex; Cl, Claustrum; Pu, putamen; CN, caudate nucleus; Ac, nucleus accumbens.

Nuclear and cytoplasmic volume deficits in 4- to 8-year-old autistic children {#Sec7}
-----------------------------------------------------------------------------

A significant, brain region--specific, developmental neuronal nucleus volume deficit was identified in 13 brain structures in autistic subjects. The neuronal nucleus volume deficit ranged from −42% in the nucleus accumbens and thalamus to −7% in the substantia nigra (Table [1](#Tab1){ref-type="table"}; Figure [1](#Fig1){ref-type="fig"}). A profound nucleus volume deficit (\>40%) was observed in the nucleus accumbens, thalamus, and claustrum; very severe (\>30%) in Purkinje cells; severe (\<30%) in the amygdala, putamen, entorhinal cortex, and MBC; moderate (\<20%) in the globus pallidus, parvocellular lateral geniculate nucleus, Ammon's horn, and inferior olive; and mild (\<10%) in the substantia nigra. In three regions (dentate nucleus, caudate nucleus, and magnocellular layer of the LGN), the difference between the neuronal nucleus volume in autistic and in control children was high, but the significance level was \>0.019 when controlling for PMI, time of fixation and dehydration, and brain weight loss during dehydration.

The mean nucleus volume deficit was significantly more prominent than the cytoplasmic volume deficit. The neuronal cytoplasm volume deficit ranged from −32% in the nucleus accumbens to −4% in the substantia nigra (Figure [1](#Fig1){ref-type="fig"}). Only in Purkinje cells was the nuclear and cytoplasmic volume deficit the same (−31%). The match between the neuronal and the nuclear volume was not recorded in the version 7.001 of Stereo Investigator that was used. For this reason, the volume of the cytoplasm was calculated as the difference between the volume of the cell body and of the cell nucleus for each structure/subject (Table [2](#Tab2){ref-type="table"}). Therefore, the significance of the difference in the volume of the neuronal cytoplasm could not be determined.Table 2**The difference between the mean volume of neuronal cytoplasm in autistic and control cohortsBrain structure4- to 8-year-old subjects11- to 23-year-old subjects29- to 64-year-old subjectsControlAutismControlAutismControlAutismMean ± SD (100%)Mean ± SD (%)Mean ± SD (100%)Mean ± SD (%)Mean (SD) (100%)Mean ± SD (%)**Nucleus accumbens900 ± 108615 ± 122 -32%864 ± 113808 ± 46 -6%758 ± 113849 ± 242 + 12%Purkinje cells11,060 ± 4667,653 ± 2,176 -31%10,899 ± 1,2619,222 ± 358 -15%10,275 ± 1,4347,735 ± 860 -25%Claustrum1,599 ± 1671,173 ± 230 -27%1,589 ± 751,358 ± 129 -15%1,518 ± 1801,415 ± 124 -7%Thalamus3,057 ± 2202,311 ± 225 -24%2,696 ± 2552,617 ± 283 -3%2,768 ± 2142,954 ± 218 + 7%Globus pallidus5,011 ± 1903,999 ± 336 -20%4,061 ± 8643,875 ± 660 -5%4,523 ± 9354,441 ± 1,008 -2%Dentate nucleus7,734 ± 9745,913 ± 1,168 -23%7,883 ± 7516,617 ± 951 -16%7,335 ± 5166,505 ± 2,047 -11%Entorhinal cortex1,862 ± 1671,434 ± 178 -23%1,948 ± 1351,597 ± 186 -18%1,969 ± 1021,980 ± 432 + 1%Amygdala2,427 ± 1251,878 ± 287 -23%2,386 ± 562,153 ± 282 -10%2,398 ± 2562,054 ± 413 -14%Magnocellular basal complex7,728 + 4756,076 ± 302 -21%7,639 ± 7507,489 ± 556 -2%7,867 ± 1,0877,563 ± 1,028 -4%Putamen1,071 ± 105914 ± 92 -15%820 ± 163758 ± 125 -8%679 ± 98770 ± 165 + 13%Caudate nucleus943 ± 106754 ± 93 -20%988 ± 148958 ± 103 -3%874 ± 160983 ± 165 + 12%Inferior olive3,852 ± 1,4283,325 ± 352 -14%3,136 ± 6773,619 ± 575 + 15%3,409 ± 6163,668 ± 72 + 8%Magnocellular LGN4,786 ± 2664,261 ± 665 -11%5,010 ± 874,855 ± 695 -3%5,119 ± 6555,230 ± 473 + 2%Parvocellular LGN2,337 ± 2802,249 ± 316 -4%2,563 ± 1562,260 ± 378 -12%2,547 ± 3562,614 ± 445 + 3%Substantia nigra8,193 ± 1,3447,847 ± 615 -4%8,147 ± 4878,271 ± 730 + 1%8,679 ± 2,27010,416 ± 1,146 + 20%Ammon's horn2,712 ± 1522,444 + 494 -10%2,972 ± 2212,515 ± 297 -3%2,892 ± 4522,752 ± 718 -5%Mean cytoplasm volume ± SD; LGN, lateral geniculate nucleus.

The difference between courses of age-associated changes in nucleus and cytoplasm volume in autistic and control group {#Sec8}
----------------------------------------------------------------------------------------------------------------------

To detect age-associated changes in neuronal nucleus volume throughout the lifespan of autistic subjects, the volume of nuclei in 16 brain regions in 4- to 8-, 11- to 23-, and 29- to 40-year-old autistic subjects was compared with that of age-matched control subjects (Table [1](#Tab1){ref-type="table"}). Whereas in 4- to 8-year-old autistic children, the nuclear volume deficit was significant in 13 of 16 regions, the number of regions with significant deficits was reduced to only two in 11- to 23-year-old autistic individuals (Table [1](#Tab1){ref-type="table"}, Figure [2](#Fig2){ref-type="fig"}), and there was no nuclear volume deficit in 29- to 60-year-old autistic subjects. The increase in neuronal nucleus volume with age in autistic subjects is reflected in the nuclei that were larger than control nuclei in the magnocellular layer of the LGN in 11- to 23-year-old autistic subjects, and the significantly larger neuronal nuclei in six of 16 regions in autistic adults 29-- 60 years of age, including the Ammon's horn, dentate nucleus, magnocellular and parvocellular layers of the LGN, caudate nucleus, and putamen. The increase in the seven other regions did not reach significance. These data indicate that the number of regions with a non-significant difference between the neuronal nucleus volume in autistic and control subjects increased from three in children, to 13 in teenagers/young adults, and ten in older adults.Figure 2**Alterations of the neuronal nucleus volume deficit throughout the lifespan of subjects diagnosed with autism.** Comparison of neuronal nucleus volume (μm^3^) in 4- to 8-year-old autistic and control subjects revealed significant nucleus volume deficits (blue arrows) in 13 of 16 brain regions examined. In 11- to 23-year-old autistic subjects, the deficit was significant in only two of 16 structures. In 29- to 64-year-old autistic subjects, differences in neuronal nucleus volume were not significant in 10 structures, whereas the volume of nuclei of autistic subjects significantly exceeded the volume of nuclei of control subjects in six other structures (white arrows).

Comparative analysis of the volume of neuronal nucleus frequency distribution in 4- to 8-year-old and 11- to 64-year-old autistic subjects versus age-matched control subjects demonstrates a high percentage of small neuronal nuclei in autistic children. However, in most of the examined regions, the difference between neuronal nucleus volume in adult autistic and in control subjects is significantly reduced or undetectable (Figure [3](#Fig3){ref-type="fig"}). These data suggest an increase of neuron nucleus volume in the autistic group and a decrease in the control group.Figure 3**Multiregional prevalence of small neuronal nuclei in 4- to 8-year-old children with autism.** Frequency distribution of neuronal nucleus volume in six selected structures demonstrates a significant shift towards small neuronal nuclei in 4- to 8-year-old autistic children (continuous line) in comparison to age-matched control subjects (dotted line), but differences between 11- to 64-year-old autistic and control subjects are significantly reduced or are undetectable.

Trajectories of neuronal nucleus volume modifications during the lifespan in autistic and control cohorts examined independently {#Sec9}
--------------------------------------------------------------------------------------------------------------------------------

To define the differences between the trajectories of age-associated alterations in neuronal nucleus volume in autism and control subjects, the volume of nuclei has been compared in three age groups within the autistic cohort and within the control cohort. The study revealed opposite trends in autistic and control cohorts (Table [3](#Tab3){ref-type="table"}, Figure [4](#Fig4){ref-type="fig"}). The dominant feature of the autistic cohort was the significant increase in the neuronal nucleus volume in eight regions in one of the older groups, including the MBC, thalamus, magno- and parvocellular layers of the LGN, inferior olive, entorhinal cortex, dentate nucleus, and claustrum. The increase observed in six other regions (substantia nigra, Ammon's horn, amygdala, nucleus, accumbens, caudate nucleus, and putamen) and Purkinje cells in cerebellum did not reach significance. A small but significant decrease of neuronal nucleus volume was found only in the globus pallidus.Table 3**Trajectory of neuronal nucleus volume changes throughout the lifespan of autistic and control subjectsBrain regionAutismControlABCDiff %** ***P value*Diff %** ***P value*ABCDiff %** ***P value*Diff %** ***P value*4--8 y11--23 y36--60 yA/BA/C4--8 y14--23 y29--64 yA/BA/C**Nucleus accumbens16321325331% 0.91155% 0.904281226239−20% 0.001−15% 0.001Purkinje cells39455265440% 0.22666% 0.468575561569−2% 0.000−1 0.402Claustrum2332553079% 0.08132% 0.000395360267−9% 0.001−32 0.000Thalamus37143358117% 0.53357% 0.000645439462−32% 0.000−28% 0.000Globus pallidus503479489−5% 0.357−3% 0.000625417478−33% 0.001−24% 0.000Dentate nucleus30548950160% 0.25764% 0.000510448397−12% 0.269−22% 0.008Entorhinal cortex4084444849% 0.85719% 0.007561502452−10% 0.632−19.6% 0.000Amygdala43152049821% 0.14016% 0.732606595548−2% 0.001−10% 0.026Magnocellular basal complex47658161122% 0.00028% 0.030656575558−12% 0.000−15% 0.064Putamen18023122328% 0.33224% 0.830246244213−1% 0.019−13% 0.007Caudate nucleus18123423429% 0.37429% 0.812256229182−11% 0.003−29% 0.000Inferior olive5075535519% 0.0899% 0.000613525508−14% 0.000−17% 0.150Magnocellular LGN38248356726% 0.40548% 0.0024554575020 0.25510% 0.189Parvocellular LGN21726333521% 0.57854% 0.000268264284−1% 0.5036% 0.436Substantia nigra7568166858% 0.911−9% 0.0358158116460% 0.367−21% 0.002Ammon's horn5766317069% 0.50923% 0.8887027026830% 0.316−3% 0.000Significance levels computed controlling for post-mortem interval, days of fixation, days of dehydration, and weight loss. Results were non-significant using a false discovery rate (FDR) of p \< 0.05. A/B and A/C not bootstrapped p-value.Figure 4**Increase of neuronal nuclei volume in teenagers and adults with autism, and decrease in control cohort.** Estimates of nucleus volume (μm^3^) in three age groups of subjects with autism revealed significant increase in eight brain regions (white arrows). In the control cohort, the volume of neurons decreased significantly in 14 regions. The significance level was computed by controlling for post-mortem interval, days of fixation, days of dehydration, and brain weight loss during dehydration. Large arrows indicate a significant difference in both age groups; small arrow marks a significant difference in one of two age groups.

The characteristic feature of the control cohort was the decrease in neuronal nucleus volume in one of the two older groups in eight regions and in both older age groups in the six other regions, including the thalamus, globus pallidus, claustrum, nucleus accumbens, caudate nucleus, and putamen. Only two regions (magno- and parvocellular layers of the LGN) did not reveal significant age-associated modifications of the neuronal nucleus volume in control cohorts. In spite of the general shift towards larger nuclei in autistic subjects and towards smaller nuclei in the control group, there are significant inter-regional differences in neuronal volume growth or reduction during the lifespan in autistic and control cohorts.

To explain why very striking differences in the mean volume of neuronal nuclei in the nucleus accumbens of children and teenagers/young adults (31% and 55%, respectively), Purkinje cells (40% and 66%, respectively), dentate nucleus (60%), amygdala (21%), putamen (28% and 24%, respectively), caudate nucleus (29% and 29%, respectively), magnocellular LGN (26%), and parvocellular LGN (21%) are not statistically significant, individual case estimates were analyzed. Comparison of the neuronal nucleus volume in four autistic children 4--8 years of age revealed prominent inter-individual differences in the mean nucleus volume as well as broad variations in the nucleus size within case.

The box plot shown in Figure [5](#Fig5){ref-type="fig"} illustrates neuronal nucleus volume distributions in the six brain structures with the most severe volume deficit and demonstrates that in all these structures, the median neuronal nucleus volumes for all four autistic children were below the range of those for the four 4- to 8-year-old control children. In the majority of autistic subjects 36--60 years of age, the neuronal nucleus volume is increased to the range of that in the control group. The box plot demonstrates an opposite pattern of changes in the 29- to 64-year-old control group, with a reduction in the median neuronal nucleus volume in comparison to that in the 4- to 8-year-old control children. The increase in the volume of the neuronal soma cytoplasm in 36- to 60-year-old autistic subjects in comparison to that in autistic children as well as the partial decrease in that volume in adult controls in comparison to in control children replicates the pattern of nuclei alterations in both cohorts.Figure 5**Difference between neuronal nucleus and cytoplasm volume distribution in control and autism group.** Box plot illustrates neuronal nucleus volume distributions in the six brain structures with the most severe volume deficit. The upper and lower boundaries of each box represent the 75^th^ and 25^th^ percentiles of nucleus volume (μm^3^), respectively. The depth of the box represents the interquartile range (IQR). The whisker above the box marks the maximum value unless any data point lies more than 1.5 times of the IQR above the 75^th^ percentile. The points outside it (outliers) are indicated by circles. The lower whisker and outliers are shown analogously. In all six brain structures, the median volumes of neuronal nuclei in autistic children were below the range of the median volumes of four 4- to 8-year-old control children. The dominant feature in 10 autistic subjects 36--60 years of age was an increase in the volume of nuclei in comparison to in autistic children, as shown as the IQR of older subjects above the median value of children. The level of 75th percentile and the whisker above the box indicate that in the older cohort, the volume of nuclei of the majority of subjects increases with age. The persistence of the volume of neuronal nuclei in the amygdala in a minority of adults at the level of that of 4- to 8-year-old children suggests heterogeneity within the autistic group and indicates a lack of neuronal nucleus increase in some autistic adults. The opposite pattern is observed in the 29- to 64-year-old control group, reflected in reduction of median neuronal nucleus volume and IQR shift below the median value of control 4- to 8-year-old children. In general, the volume of cytoplasm increases with age in adult autistic subjects and decreases in the control group.

Discussion {#Sec10}
==========

Global pattern of abnormal neuron growth in autism {#Sec11}
--------------------------------------------------

Morphometric studies designed to detect clinicopathological correlations demonstrated links between functional deficits observed in autism, and reduced size of neurons in several cortical regions including superior and middle frontal gyrus \[[@CR42]\], inferior frontal cortex (BA 44 and 45) \[[@CR32]\], fusiform gyrus \[[@CR34]\], anterior midcingulate \[[@CR43]\] and anterior cingulate cortex \[[@CR44]\], as well as Purkinje cells in the cerebellum \[[@CR45]\], and neurons in the brainstem superior olive \[[@CR46]\]. In addition, neuropathological studies not supported with morphometric methods revealed small neurons in the amygdala, entorhinal cortex, mammilary body, \[[@CR47]\], Ammon's horn \[[@CR48]\], medial septal nucleus \[[@CR49]\], cerebellar nuclei and inferior olive \[[@CR50]\]. The present study of neuronal nucleus and cytoplasm volumes and our previous study of cell soma volume in 14 brain regions \[[@CR27]\], combined with parallel studies of several cortical regions in the same cohort, and neuropathological studies listed in Table [4](#Tab4){ref-type="table"}, disclose the global nature of developmental alterations with multiregional developmental alterations rather than changes limited to a few regions. The detected pattern of developmental alterations of neuronal growth may contribute to the diagnostic features of ASD, as well as a number of associated conditions, including intellectual deficits, depression, obsessive-compulsive disorders, anxiety, oppositional/defiant disorder, aggression, and self-injurious behaviors \[[@CR51],[@CR52]\]. The absence of significant neuronal soma alterations in cortical regions with little-known relevance to autism, such as posteroinferior occipitotemporal gyrus \[[@CR53]\], primary visual cortex \[[@CR34]\] and prefrontal cortex \[[@CR54]\] support the specificity of neuropathological changes in autism. The broad spectrum of deficits of neuronal soma, nucleus, and cytoplasm volume shown in this study reveals brain region/neuron type-specific sub-patterns of developmental abnormalities in autism.Table 4**Neuronal soma, nucleus and cytoplasm volume deficit in 4- to 8-year old autistic subjects compared to results of previous qualitative and morphometric studiesBrain structure or neuron typeVolume deficit in 4- to 8-year-old autistic subjectsAlterations of neuron soma size detected in previous studiesNucleusCytoplasmSomaN. accumbens−42%\*−32%−34%\*Thalamus−42%\*−24%−27%\*Claustrum−41%\*−27%−29%\*Purkinje cells−31%\*−31%−31%\***24% Purkinje cell area deficit \[[@CR45]\]**Amygdala−29%\*−23%−24%\***Reduced neuron soma size in some amygdala nuclei \[[@CR47]\]**Magnocellular basal complex−27%\*−21%−22%\*Putamen−27%\*−15%−17% nsEntorhinal cortex−27%\*−23%−24%\***Reduced neuron soma size \[[@CR47]\]**Globus pallidus−19%\*−20%−20%\*Parvocellular LGN−19%\*−4%−5%\*Ammon's horn−18%\*−10%−12%\***27% neuron volume deficit in CA4 of 9 y old \[[@CR48]\]**Inferior olive−17%\*−14%−14% ns**Enlarged neurons in less than 12 years old and smaller in over the age of 22 years \[[@CR50]\]**Substantia nigra−7%\*−4%−5%\*Magnocellular LGN−16% ns−11%−12%\*Caudate nucleus−29% ns−20%−22%\*Dentate nucleus−40% ns−23%−25%\***Enlarged neurons in less than 12 years old and smaller in over the age of 22 years \[[@CR50]\]**Superior olive\* Significant neuron volume deficit in medial superior olive** \[[@CR46]\]**Superior and middle frontal gyrus\*Significantly smaller neurons in six autistic subjects 4 to 24 years of age** \[[@CR42]\]**Inferior frontal cortex (BA 44 and 45)\*Significant neuron volume deficit by 18% in layer III and V, and by 22% in layer VI** \[[@CR32]\]**Fusiform gyrus\*Significant neuron volume deficit by 21% in layer V and by 13.4% in layer VI** \[[@CR34]\]**Anterior midcingulate cortex\*Significant pyramidal neurons volume deficit in young children** \[[@CR43]\]**Posteroinferior occipitotemporal gyrus\*No significant difference in pyramidal neurons volume** \[[@CR53]\]**Prefrontal cortex\*Unchanged size of neurons** \[[@CR54]\]Anterior cingulate cortexSignificant neuron volume deficit in layers I-III and V-VI \[[@CR44]\]Mammillary bodySmaller neurons \[[@CR47]\]Medial septal nucleusSmaller neurons \[[@CR49]\]Fastigial, globose, emboliform nucleusEnlarged neurons in less than 12 years old and smaller in over the age of 22 years \[[@CR50]\]The 16 regions marked with bold were examined in this study. The superior olivary complex and six neocortical regions marked with bold (\*) were examined by other researchers using significant amount of material from this cohort of 14 autistic and 14 control subjects. The significance of difference of the cytoplasm volume was not determined due to software limitations.

Patterns of age-associated nucleus and cytoplasm changes throughout the lifespan in autistic and control groups {#Sec12}
---------------------------------------------------------------------------------------------------------------

The present study demonstrates that alterations of neuronal soma volume in autism are associated with alterations of the nucleus and cytoplasm volumes, and that the volumes of these two neuronal body compartments is the lowest in 4- to 8-year-old autistic children. The detected brain region- and neuron type-specific neuronal volume deficit suggests that this developmental abnormality is established before 4 years of age. Because diagnosis is made at the age of 3 years or older, verification of this hypothesis on the basis of current diagnostic criteria is impossible. However, a study of neuronal progenitor cells suggests that in autism, neuronal size might be defined at age much less than 3 years. The exposure of human neuronal progenitor cells originating from the fetal cerebral cortex to media enriched with serum from autistic donors \~3 years of age or from age-matched healthy donors revealed that in colonies that developed in "autistic" conditions, the percentage of smaller cells was significantly higher than in colonies exposed to sera of healthy donors \[[@CR55]\].

Whereas nuclear volume deficit was significant in 13 of 16 regions in 4- to 8-year-old autistic children, the number of regions with a significant deficit was reduced to only two in 11- to 23-year-old autistic individuals, and there was no nuclear volume deficit in 29- to 60-year-old autistic subjects. These findings suggest that in autistic subjects, deceleration of neuronal nuclear and cytoplasmic growth during childhood is followed by acceleration of neuronal volume growth during adolescence and early adulthood. The detected pattern explains the differences between characteristics of neuronal size in other reports. In our cohort, the significant difference in volume of neuronal soma (−24%) or nucleus in the amygdala (−29%; p \< 0.001) was detected only in the youngest autistic subjects (4--8 years of age), and the difference in nucleus and cell volume was not significant in older groups (11--64 years of age). This result is similar to the result of averaging of the neuronal size in the amygdala of 10- to 44-year-old autistic subjects \[[@CR56]\], when the difference is masked by an increase in the neuronal volume in autistic subjects and a decrease in the neuronal volume in control subjects.

Common mechanisms contributing to smaller neuron size in neurodevelopmental disorders {#Sec13}
-------------------------------------------------------------------------------------

Autism and Rett syndrome overlap phenotypically and neuropathologically. In both conditions, a similar delayed regression after apparently normal prenatal and early postnatal development is observed \[[@CR57]\]. Rett syndrome is caused by over 300 mutations of the *methyl-CpG-binding protein 2 (MECP2)* gene \[[@CR58],[@CR59]\]. The *MECP2* gene encodes methyl CpG--binding protein-1 (MeCP2), a transcriptional repressor required for proper development of post-migratory neurons, but with cell-specific differences in MeCP2 levels \[[@CR60]\]. In Rett syndrome, normal head circumference at birth, but deceleration of growth at 2--3 months of age results in a 12--34% deficit in brain weight and volume \[[@CR61],[@CR62]\], reduced neuronal size in the cortex, thalamus, basal ganglia, amygdala, and hippocampus \[[@CR63]\], decrease in the size of cortical minicolumns \[[@CR64]\], and reduced dendritic branching \[[@CR65]\]. Furthermore, the reduced size of pyramidal neurons and the lesser complexity of dendritic arborizations in MeCP2 mutant mice indicate that MeCP 2 is involved in maturation and the maintenance of neurons, including dendritic integrity and synaptogenesis \[[@CR66],[@CR67]\]. The significant reduction in MeCP2 expression in 79% of autism, 100% of Angelman syndrome, 75% of Prader-Willi syndrome, and 60% of Down syndrome cases \[[@CR57]\] compared to age-matched controls suggests that altered MeCP2 expression contributes to abnormal postnatal brain development and to an abnormal course of neuron maturation in neurodevelopmental disorders \[[@CR68]\].

MeCP2 is an abundant nuclear protein with elevated expression during postnatal brain development \[[@CR60]\]. The chromatin-binding function of MeCP2 is required for neuronal nucleus and nucleolus development and maturation. Critical for this binding activity is an intact methyl-binding domain at the amino terminus of the MeCP2 protein \[[@CR69]\]. During neuronal maturation, the nuclear morphology changes from a small, heterochromatic nucleus with many randomly located chromocenters and several nucleoli to a large, mostly euchromatic nucleus with fewer and larger chromocenters and a large, centrally located nucleolus \[[@CR70]\]. In the absence of MeCP2, the neuronal nuclei fail to increase in size at normal rates during cell differentiation. Neurons lacking MeCP2 have a significantly reduced rate of RNA synthesis; however, re-expressing MeCP2 in mutant neurons rescues the nuclear size phenotype *in vitro* \[[@CR71]\] and in *Mecp2* mice \[[@CR72]\]. Reduced expression of MeCP2 in the majority of autistic subjects \[[@CR57]\] appears to contribute to nucleus volume deficit.

Alterations that may contribute to neuronal cytoplasm volume changes throughout the lifespan of autistic individuals {#Sec14}
--------------------------------------------------------------------------------------------------------------------

One may hypothesize that the increase in neuronal soma, nucleus, and cytoplasm volume in autistic adolescents corresponds to delayed cell development/maturation. However, this assumption appears to be in conflict with biochemistry- and immunocytochemistry-supported neuropathological studies that demonstrate a broad spectrum of pathology in the neuronal energy-generating system, metabolism, degradation and storage systems, and oxidative stress. These alterations affect major cytoplasmic compartments, including mitochondria, endocytic vesicles, lysosomes, and autophagic vacuoles, as well as lipofuscin deposits and suggest that they may directly contribute to the abnormal increase in cytoplasm volume in adolescence/adulthood.

Mitochondria are one of the major compartments of neuronal cytoplasm. Mitochondrial DNA mutations and copy number variations \[[@CR73]-[@CR75]\] support the hypothesis of a mitochondrial pathology in ASD. Developmental alterations include the perturbations of mitochondrial energy generation that have been demonstrated in some individuals diagnosed with ASD \[[@CR76]-[@CR80]\], and mitochondrial respiratory chain dysfunction \[[@CR75]\].

Mitochondrial electron transport chain (ETC) complexes generate the proton gradient used by ATP synthase to catalyze ATP formation \[[@CR81],[@CR82]\]. In autistic subjects, alterations of ETC reveal brain region--specific differences, with a decrease in the ETC protein levels in the cerebellum and frontal and temporal cortices, but not in the occipital and parietal cortices. Chauhan *et al*. \[[@CR80]\] reported a significant reduction in respiratory chain protein expression, with lower levels of complexes II, III, and IV in the temporal cortex of autistic children. ETC alterations are associated with age. Children with autism 4--10 years of age have lower levels of ETC proteins than control subjects; however, the difference in subjects from 14--39 years of age was not significant \[[@CR75],[@CR80]\]. Decreased complexes III and IV were also reported by Tang *et al.* \[[@CR83]\].

Cytoplasm volume changes might be directly related to increased mitochondrial mass, as measured by levels of the mitochondrial membrane proteins porin, Tom20, and Tim23, and significant changes in the expression of mitochondrial fission and fusion proteins, suggesting the imbalance between mitochondrial biogenesis and degradation in neurons in the temporal cortex of young ASD subjects \[[@CR83]\]. These alterations can change the morphology, number, and function of mitochondria \[[@CR84]\]. Autophagosomes degrade damaged mitochondria, producing excessive reactive oxygen species via ubiquitin-mediated recognition and selective targeting \[[@CR85]\]. Several ubiquitin genes have been implicated in ASD \[[@CR86]\], including PARK2 that encodes parkin, which assists in mitochondria dystruction \[[@CR87]\]. However, an increase in compromised mitochondria suggests impaired mitophagy in ASD \[[@CR83]\].

Reported mitochondrial alterations reflect the disturbed energy production that coexists with alterations of neuronal metabolism \[[@CR75],[@CR88]-[@CR90]\] and the enhanced degradation of DNA, RNA, and proteins by oxidative stress \[[@CR80],[@CR91],[@CR92]\] that may result in enhanced cell organelle turnover \[[@CR77]\], excessive accumulation of products of degradation \[[@CR93]\], and pathological increase of the cytoplasm and cell volume.

Enhanced anabolic APP processing in autism {#Sec15}
------------------------------------------

Alternative cleavage of amyloid-β precursor protein (APP) with α secretase releases non-amyloidogenic secreted APPα (sAPPα) \[[@CR94]\]. Recent studies revealed enhanced non-amyloidogenic cleavage of APP with α and γ secretases in such developmental disorders as autism and fragile X syndrome (FXS) \[[@CR88],[@CR95]-[@CR98]\]. Sokol *et al.* \[[@CR95]\] and Ray *et al.* \[[@CR89]\] reported two or more times higher levels of total sAPP, including sAPPα, and a decrease in the levels of both Aβ40 and Aβ42 in young children with severe autism in comparison to children without autism. A study of 25 autistic subjects revealed elevated plasma sAPPα in 60% of children with autism (n = 25) compared to healthy controls \[[@CR98]\]. The elevated levels of sAPPα in autistic individuals with severe autism but not in neurotypical and mildly autistic subjects suggest a link between levels of sAPPα and autism severity \[[@CR89]\].

Neurons in the brain of control children and adults accumulate cell type--specific amounts of Aβ~17--40/42~, which is the product of nonamyloidogenic APP processing with α- and γ-secretase \[[@CR99]\]. The enhanced cytoplasmic accumulation of mainly N-terminally truncated Aβ was detected in 11 of 12 examined brain regions in autistic children, adolescents, and adults diagnosed with Dup15q11.2-q.13 (dup15) and in 8 of 12 regions in children, adolescents, and adults with idiopathic autism, including neurons in all three cortical regions, the amygdala, thalamus, Purkinje cells, lateral geniculate nucleus, and dentate nucleus \[[@CR100]\]. Enhanced non-amyloidogenic APP metabolism is associated with excessive accumulation of Aβ~17--40/42~ within the organelles involved in proteolysis and storage of metabolic remnants \[[@CR92]-[@CR100]\]. One may hypothesize that the observed neuron type- and region-specific increase in the volume of neuronal cytoplasm is a reflection at least in part of a neuron type- and region-specific increase in sAPPα production and neuron type- and region-specific enhanced accumulation of Aβ~17--40/42~ in several cytoplasmic compartments, including endocytic vesicles, autophagic vacuoles, lysosomes, and lipofuscin, and in minute amounts in mitochondria. Application of Lamp 1 as a lysosomal marker revealed that approximately 20--30% of neuron cytoplasmic Aβ~17--40/42~ is detected in the endolysosomal pathway, whereas another 20--30% of neuronal Aβ~17--40/42~ is accumulated in the lipofuscin \[[@CR92],[@CR100]\]. An increase in the percentage of Aβ~17--40/42~-accumulating neurons appears to be associated with an increase in the number of lipofuscin-containing neurons observed in our study \[[@CR100]\] and in an increase in the number of lipofuscin-containing neurons by 69% in Brodmann area 22, by 149% in area 39, and by 45% in area 44 \[[@CR93]\]. The higher prevalence of excessive Aβ~17--40/42~ in autistic subjects with dup(15), the early onset of intractable seizures, and the high risk of SUDEP support reports demonstrating a link between enhanced sAPPα levels and severe autism \[[@CR88],[@CR89],[@CR95],[@CR98]\]. The appearance of diffuse plaques in three autistic subjects 39--53 years of age suggests an age-associated risk of alterations of APP processing with enhanced short-form Aβ deposition in the cytoplasm and full length of Aβ in nonfibrillar plaques \[[@CR101]\].

Biochemical reports demonstrate an increase in the level of marker of lipid peroxidation (malondialdehyde, MDA) in the plasma of autistic children \[[@CR102]\] and in the cerebral cortex and cerebellum \[[@CR103]\]. Lipid peroxidation products were detected in all mitochondria and lipofuscin deposits, numerous autophagic vacuoles, and lysosomes. Neuronal Aβ was colocalized with markers of oxidative stress, including 4-hydroxy-2-nonenal (HNA) and MDA, and increased levels of Aβ levels correlated with higher levels of HNE and MDA \[[@CR92]\].

It appears that a neuron type- and region-specific pattern of these metabolic changes and oxidative stress contribute to the cytoplasmic organelle damage, degradation and storage of products of degradation in growing lipofuscin deposits, and the cell cytoplasm alterations detected in this study. The prevalence of this pathology in children/young autistic subjects but with no evidence of significant neuronal loss suggests that oxidative damage of cytoplasmic organelles is associated with an increased turnover/repair of affected cell components. In addition, some reports suggest that increased processing of APP may contribute to autistic functional alterations \[[@CR89],[@CR95]\].

Conclusions {#Sec16}
===========

This first study of the volume of neuronal nucleus and cytoplasm in autistic subjects reveals a brain region-- and neuron type--specific deficit in the volume of both cell compartments in affected 4-to 8-year-old children compared to control subjects. The most severe volume deficit in the youngest group suggests that these developmental abnormalities contribute to emergence of the autistic phenotype before the age of three years. Significant pathology in 13 of 16 examined regions reflects the global nature of developmental deficits and their potential contribution to a broad spectrum of clinical autism manifestations. The observed pattern of nuclear and cytoplasmic alterations suggests four neuron type- and brain region-specific phases of changes in neuron morphology: (a) abnormal as well as delayed neuronal nucleus and cytoplasmic growth before the third year of life, (b) severe volume deficit in early childhood (4--8 years) reflecting developmental abnormalities in first three years of life, (c) significant increase in neuronal nucleus and cytoplasmic volume during adolescence, and (d) relatively modest further modifications during adulthood. The increase in nuclear and cytoplasmic volumes close to the control level in the majority of examined regions in teenagers and adults appears to reflect alterations in neuronal energy production, metabolism, and oxidative stress, rather than delayed neuron growth with an adjustment of structure and function.

Consent {#Sec17}
=======
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